Regeneron Stock

REGN Stock: When Bad News Is Good News The cross-hairs are pointed directly at the biotechnology sector, as the Donald Trump administration is set to announce its policies on how it will deal with the predatory pricing polices that have tarnished the face of this industry. I have the…

REGN Stock: Constructive Developments Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported earnings on May 4, 2017, and although it missed on the bottom line, REGN stock is still surging higher by 5.51% on the back of a positive reinforcement of forward guidance. I have been starting to focus on biotechnology stocks…

REGN Stock: This Bear Is Fierce 2016 was a disappointing year for REGN stock, and 2017 is not faring any better as it is off to a poor start. On Thursday January 5, a U.S Federal judge ruled that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR)(NYSE:SNY) have infringed on…

REGN Stock: Bullish Biotechs Donald Trump's election victory sent biotech stocks screaming higher as the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB), which acts as a proxy for this sector, was up 7.44% on Wednesday morning. This reaction to the election is a classic example of "sell on the rumor,…

REGN Stock: Resumption of the Bull Biotech stocks are one of my favorite sectors because, after living through a number of bull markets, I have learned that the best performing stocks in a bull market are the ones with the highest beta. Beta measures a stock's sensitivity to moves…